| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_755f0e063405a160b3444126780baba9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e94a2847deb86056ccb7bbf816a27450
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_15285142deddfee573851ab2ab5319e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f4621ac660115838bcf030e0d4f7ddd2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f6309fcb38cd943c73c90103766e233c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8c452fc1bd8ff6c00d9e8170515e6579 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D257-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D257-04 |
| filingDate |
2007-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_650706288248eb3c019b003215508d3e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e15698d27c8aa84466263481cc72c508
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74f991037114d7cbb02fb4b5e02f8f3e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f14d4267bc180c6d26c7e8cff0e8c093
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d906f50bc51f7d56d134010bf7aa622b |
| publicationDate |
2008-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2008004110-A2 |
| titleOfInvention |
Process for the preparation of the angiotensin ii antagonist valsartan |
| abstract |
The present invention provides a method for the preparation of N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine (Valsartan) which comprises; treating N-[[2'-(1-triphenylmethyl-tetrazol-5-yl)biphenyl-4-yl]methy]-L-valine methyl ester (X)with oxalic acid or its hydrates in a solvent to produce N-[[2'-(1-triphenylmethyl-tetrazol-5-yl)biphenyl-4-yl]methy]-L-valine methyl ester oxalate (Xa) and treating the compound (Xa) with a base in a solvent followed by reacting with valeryl chloride in presence of base in a solvent to produce N-[[2'-(1-triphenylmethyl-tetrazol-5-yl)[1,1'biphenyl]-4-yl]methyl]-N-valeryl-L-valine methyl ester (XI), de-protecting the compound (XI) using anhydrous acidic conditions to produce N-(1-oxopentyl)-N-[[2'-(1-H-tetrazol-5-yl)[1,1'biphenyl]-4-yl]methyl-L-valine methyl ester (V) followed by treating with base in a solvent to produce Valsartan. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102596899-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011051213-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102649780-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008135762-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2316821-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8288561-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101163864-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8492577-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009125416-A2 |
| priorityDate |
2006-07-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |